Serum-free cell culture medium

Patent metadata

Field	Value
Publication number	US-12331341-B2
Application number	US-202217712697-A
Country	US
Kind code	B2
Filing date	Apr 4, 2022
Priority date	Mar 15, 2013
Publication date	Jun 17, 2025
Grant date	Jun 17, 2025

Abstract

The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

First claim

What is claimed is:

1. A method for cultivating CHO cells, comprising the steps of: (a) providing a cell culture medium which is serum-free, comprising 0.6±0.09 mM ornithine and 0.714±0.11 mM putrescine, and (b) propagating or maintaining the CHO cells in the cell culture medium to form a cell culture, wherein the cells express aflibercept, wherein the cell culture has a greater viable cell culture density than an equivalent aflibercept-expressing CHO cell culture grown in a cell culture medium that is supplemented with no more than 2.5 μM putrescine and no ornithine.

2. The method of claim 1 , further comprising the step of adding one or more point-of-use additions to the cell culture medium.

3. The method of claim 2 , wherein the point-of-use additions comprise one or more of NaHCO 3 , glutamine, insulin, glucose, CuSO 4 , ZnSO 4 , FeCl 3 , NiSO 4 , Na 4 EDTA, and Na 3 Citrate.

4. The method of claim 3 , wherein each of NaHCO 3 , glutamine, insulin, glucose, CuSO 4 , ZnSO 4 , FeCl 3 , NiSO 4 , Na 4 EDTA, and Na 3 Citrate are added to the medium as point-of-use additions.

5. The method of claim 1 , wherein the cell culture medium is hydrolysate-free or is chemically defined.

6. The method of claim 1 , wherein the cell culture medium comprises:
(a) a mixture of amino acids or salts thereof;
(b) one or more fatty acids;
(c) a mixture of nucleosides; or
(d) one or more divalent cations.

7. The method of claim 6 , wherein the mixture of amino acids or salts thereof are at a concentration of ≥40 mM±6 mM in the cell culture medium.

8. The method of claim 6 , wherein the mixture of amino acids or salts thereof comprises one or more of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.

9. The method of claim 6 , wherein the one or more fatty acids are selected from the group consisting of linoleic acid, thioctic acid, oleic acid, palmitic acid, stearic acid, arachidic acid, arachidonic acid, lauric acid, behenic acid, decanoic acid, dodecanoic acid, hexanoic acid, lignoceric acid, myristic acid and octanoic acid.

10. The method of claim 6 , wherein the mixture of nucleosides comprises one or more of adenosine, guanosine, cytidine, uridine, thymidine, and hypoxanthine.

11. The method of claim 6 , wherein the divalent cation is Ca 2+ , Mg 2+ , or both.

12. The method of claim 1 , wherein the CHO cells are CHO cell derivatives.

13. The method of claim 1 , wherein the CHO cells are CHO DUX B-11 cells, Veggie-CHO cells, GS-CHO cells, S-CHO cells, or CHO lec mutant cells.

14. The method of claim 1 , wherein the CHO cells are CHO-K1 cells.

Assignees

• Regeneron Pharma

Inventors

• Oshodi Shadia Abike
• Johnson Amy S
• Lawrence Shawn M

Classifications

• C12N2500/34

  Sugars · CPC title

• C12N2500/24

  Iron; Fe chelators; Transferrin · CPC title

• C12N2500/22

  Zinc; Zn chelators · CPC title

• C12N5/0682

  Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609) · CPC title

• C12N2510/02

  Cells for production · CPC title